For healthy older adults, taking aspirin daily for years does not reduce the risk of heart attacks or strokes in the long run, even though it may seem to help slightly while being taken.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of all RCTs of aspirin for primary prevention in adults aged 70+ would definitively determine whether any population subgroup benefits from long-term MACE reduction.
A systematic review and meta-analysis pooling individual participant data from all completed RCTs comparing daily low-dose aspirin (75–100 mg) versus placebo in adults aged 70+ without CVD, with minimum 5-year follow-up, standardized MACE definitions (non-fatal MI, ischemic stroke, CVD death), and stratification by age, sex, diabetes, and baseline CVD risk score.
A new RCT could confirm whether aspirin reduces MACE in a specific high-risk subgroup of older adults (e.g., those with elevated Lp(a) or high coronary calcium score).
A double-blind RCT of 8,000 adults aged 70–80 with elevated coronary artery calcium scores (>400 Agatston units) and no prior CVD, randomized to 100 mg aspirin or placebo daily for 7 years, with primary outcome being time to first MACE, secondary outcomes including all-cause mortality and hemorrhage, and adherence monitored via pill counts and serum salicylate levels.
A cohort study could assess whether aspirin use in older adults is associated with reduced MACE in real-world settings with varying adherence and comorbidities.
A prospective cohort of 15,000 adults aged 70+ without CVD, stratified by aspirin use (initiator, continuing, non-user), with annual cardiovascular risk assessments, medication reconciliation, and MACE events adjudicated via medical records over 10 years, adjusting for statin use, blood pressure, and smoking.
A case-control study could identify whether aspirin users who develop MACE differ in prior medication patterns or biomarkers compared to non-users who develop MACE.
A nested case-control study within a primary care database comparing 1,200 older adults with incident MACE to 3,600 matched controls, assessing aspirin use (duration, dose, timing) and biomarkers (hs-CRP, Lp(a), fibrinogen) in the 2 years prior to event, with exposure data validated via pharmacy records.
A cross-sectional survey could estimate the proportion of older adults taking aspirin who report prior cardiovascular events, but cannot determine causality.
A national survey of 10,000 adults aged 70+ asking about current aspirin use and history of heart attack or stroke, with self-reported events confirmed by medical records, to estimate prevalence of MACE among aspirin users versus non-users at a single time point.